AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer

Current Opinion in Investigational Drugs

Volumn 11, Issue 12, 2010, Pages 1442-1449

  Kimura, Shinya ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; BCR ABL PROTEIN; JANUS KINASE 2; PACLITAXEL;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW SUPPRESSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; UREA;

EID: 79952772144     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M et al NAT MED 2004 10 3 262-267 (Pubitemid 38667616)
2. The cellular geography of Aurora kinases. Carmena M, Earnshaw WC NAT REV MOL CELL BIOL 2003 4 11 842-854 (Pubitemid 37411723)
3. A homologue of Drosophila Aurora kinase is oncogenic and amplifed in human colorectal cancers. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS et al EMBO J 1998 17 11 3052-3065 (Pubitemid 28254378)
4. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and CENP-E to kinetochores. Ditchfeld C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS J CELL BIOL 2003 161 2 267-280 (Pubitemid 36529846)
5. Characterisation of Aurora kinase inhibitors derived from fragment based lead discovery. Gallagher N, Lyons J, Curry J, Reule M, Berdini V, Tisi D, Fazal L, Howard S, Wyatt P, Gill A PROC AM ASSOC CANCER RES 2006 47 Abs 4915
6. Astex Therapeutics company webpage. Astex Therapeutics Ltd COMPANY WORLD WIDE WEB SITE 2007 January 17
7. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I Bcr-Abl mutation. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ BLOOD 2007 109 2 500-502 (Pubitemid 46105945)
8. Discovery, synthesis and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase. Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJM, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T et al J MED CHEM 2007 50 9 2213-2224 (Pubitemid 46683074)
9. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET et al PROC NATL ACAD SCI USA 2007 104 10 4106-4111 (Pubitemid 47181586)
10. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF et al CLIN CANCER RES 2007 13 12 3682-3688 (Pubitemid 46955132)
11. A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies. Ravandi F, Foran J, Verstovsek S, Cortes J, Wierda W, Boone P, Borthakur G, Sweeney T, Kantarjian H BLOOD 2007 110 11 Abs 904
12. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DVJ, Sawyers CL et al CANCER RES 2006 66 2 1007-1014 (Pubitemid 43168337)
13. TG101209, a small molecule Jak2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated Jak2V617F and MPLW515L/K mutations. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R et al LEUKEMIA 2007 21 8 1658-1668 (Pubitemid 47086756)
14. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profle relevant to cancer. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L et al MOL CANCER THER 2007 6 12 3158-3168
15. AT9283, a potent inhibitor of Bcr-Abl T315I, is active in CML models. Squires MS, Reule M, Curry JE, Mallett K, Yule M, Tanaka R, Thompson N, Lyons J, Kimura S AM ASSOC CANCER RES ANN MEET 2008 99 April 14 Abs 2820
16. Effcacy of TG101348, a selective Jak2 inhibitor, in treatment of a murine model of Jak2V617F-induced polycythemia vera. Werning G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC et al CANCER CELL (ONLINE) 2008 13 4 311-320 (Pubitemid 351446195)
17. Crystal structure of the T315I Abl mutant in complex with the Aurora kinases inhibitor PHA-739358. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A et al CANCER RES 2007 67 17 7987-7990 (Pubitemid 47395130)
18. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R et al CLIN CANCER RES 2006 12 13 4080-4089 (Pubitemid 44078096)
19. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant Bcr-Abl mutations including T315I. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brummendorf TH BLOOD 2008 111 8 4355-4364
20. Phase I and pharmacodynamic trial of AT9283, an Aurora kinase inhibitor, in patients with refractory leukemia. Foran JM, Ravandi F, O'Brien SM, Borthakur G, Rios M, Boone P, Worrel J, Mallett KH, Squires M, Fazal LH, Kantarjian HM J CLIN ONCOL 2008 26 20 Suppl Abs 2518
21. A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. Plummer ER, Calvert H, Arkenau H, Mallett KH, Squires M, Smith D, Lewis S, Judson I J CLIN ONCOL 2008 26 20 Suppl Abs 2519
22. LS104, a non-ATP-competitive small-molecule inhibitor of Jak2, is potently inducing apoptosis in Jak2V617F positive cells. Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, Huber C, Fischer T MOL CANCER THER 2008 7 5 1176-1184
23. Vertex Pharmaceuticals highlights telaprevir progress and reports second quarter 2008 results. Vertex Pharmaceuticals Inc PRESS RELEASE 2008 July 31
24. A pentacyclic Aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability. Rawson TE, Ruth M, Blackwood E, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Georges GJ, Goller B, Halladay J et al J MED CHEM 2008 51 15 4465-4475
25. Identifcation of N-(4-piperidinyl)-4-(2,6-dichlorobenzoyl amino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, Davis DJ, Devine LA, Early TR, Feltell RE, Lewis EJ et al J MED CHEM 2008 51 16 4986-4999
26. Identifcation of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han HY, Von Hoff DD, Hurley LH MOL CANCER THER 2006 5 7 1764-1773 (Pubitemid 44323244)
27. Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity. Howard S, Berdini V, Curry J, Gill AL, Richardson CJ, Rees D, Reule M, Tisi D, Wyatt P, Fazal L EJC SUPPL 2008 6 12 Abs 287
28. Discovery of a potent and selective Aurora kinase inhibitor. Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris S, Heumann SA et al BIOORG MED CHEM LETT 2008 18 17 4880-4884
29. Activity of the multi-targeted kinase inhibitor, AT9283 on imatinib-resistant CML models. Tanaka R, Squires MS, Kimura S, Yokota A, Mallett K, Smyth T, Thompson NT, Nagao R, Yamauchi T, Ushiki T, Lyons JF et al BLOOD 2008 112 11 Abs 1104
30. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M et al J MED CHEM 2009 52 2 379-388
31. NCT00443976: Aurora kinase inhibitor AT9283 in treating patients with advanced or metastatic solid tumors or non-Hodgkin's lymphoma. Astex Therapeutics Ltd CLINICALTRIALS.GOV 2007
32. NCT00522990: Study to assess the safety of escalating doses of AT9283, in patients with leukemias. Astex Therapeutics Ltd CLINICALTRIALS.GOV 2007
33. A phase I study of AT9283, an Aurora kinase inhibitor, in patients with refractory solid tumors. Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER, Lock V, Squires M, Fazal L, Judson I J CLIN ONCOL 2009 27 15 Suppl Abs 2566
34. A unique clonal Jak2 mutation leading to constitutive signalling causes polycythaemia vera. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL et al NATURE 2005 434 7037 1144-1148 (Pubitemid 40663494)
35. Jak2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ et al N ENGL J MED 2007 356 5 459-468 (Pubitemid 46193073)
36. Antimyeloma activity of a small molecule multi-targeted kinase inhibitor, AT9283, via potent Aurora kinase and Stat3 inhibition. Santo L, Hideshima T, Cirstea D, Nelson EA, Bandi ML, Gorgun G, Vallet S, Pozzi S, Patel K, Ikeda H, Perrone G et al AM ASSOC CANCER RES ANN MEET 2010 101 April 19 Abs 2530
37. AT9283, a small molecule multi-targeted kinase inhibitor induces antimyeloma activity via potent Aurora kinase and Stat3 inhibition. Santo L, Hideshima T, Nelson EA, Cirstea D, Bandi M, Ikeda H, Gorgun G, Vallet S, Pozzi S, Perrone G, Patel K et al BLOOD 2009 114 22 Abs 3833
38. NCT01145989: A study of AT9283 in patients with relapsed or refractory multiple myeloma. NCIC Clinical Trials Group CLINICALTRIALS.GOV 2010
39. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Dawson MA, Curry JE, Barber K, Beer PA, Graham B, Lyons JF, Richardson CJ, Scott MA, Smyth T, Squires MS, Thompson NT et al BR J HAEMATOL 2010 150 1 46-57
40. Aurora B kinase inhibition in mitosis strategies for optimising the use of Aurora kinase inhibitors such as AT9283. Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, Wallis N CELL CYCLE 2009 8 12 1921-1929
41. Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant Bcr-Abl positive leukemic cells. Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyons JF et al BLOOD 2010 116 12 2089-2095
42. Aurora-kinase inhibitors as anticancer agents. Keen N, Taylor S NAT REV CANCER 2004 4 12 927-936 (Pubitemid 39626216)
43. Aurora-A, a guardian of poles. Marumoto T, Zhang DW, Saya H NAT REV CANCER 2005 5 1 42-50
44. Aurora kinases: New targets for cancer therapy. Carvajal RD, Tse A, Schwartz GK CLIN CANCER RES 2006 12 23 6869-6875 (Pubitemid 44974478)
45. Drosophila Aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. Giet R, Glover DM J CELL BIOL 2001 152 4 669-681 (Pubitemid 34280153)
46. The Aurora kinases: Role in cell transformation and tumorigenesis. Katayama H, Brinkley WR, Sen S CANCER METASTASIS REV 2003 22 4 451-464 (Pubitemid 36791899)
47. A gain-of-function mutation of Jak2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC N ENGL J MED 2005 352 17 1779-1790 (Pubitemid 40570926)
48. Activating mutation in the tyrosine kinase Jak2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofbrosis. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska L, Clark JJ, Moore S, Adelsperger J et al CANCER CELL (ONLINE) 2005 7 4 387-397 (Pubitemid 40544655)
49. MPLW515L is a novel somatic activating mutation in myelofbrosis with myeloid metaplasia. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ et al PLOS MED (PRINT) 2006 3 7 1140-1151 (Pubitemid 44125998)
50. Mechanisms of disease-Chronic myeloid leukemia-Advances in biology and new approaches to treatment. Goldman JM, Melo JV N ENGL J MED 2003 349 15 1451-1464 (Pubitemid 37211061)
51. Novel agents to override imatinib resistance mechanisms. Yokota A, Kimura S DRUG DEV RES 2008 69 7 398-406
52. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: For overriding Bcr-Abl/T315I. From the second to third generation. Tanaka R, Kimura S EXPERT REV ANTICANCER THER 2008 8 9 1387-1398
53. Validating Aurora B as an anti-cancer drug target. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS J CELL SCI 2006 119 17 3664-3675 (Pubitemid 44501870)
54. Mitotic requirement for Aurora A kinase is bypassed in the absence of Aurora B kinase. Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, Ye X FEBS LETT 2005 579 16 3385-3391 (Pubitemid 40800286)
55. Progress in the development of selective inhibitors of Aurora kinases. Mortlock A, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson R, Green S CURR TOP MED CHEM 2005 5 2 199-213 (Pubitemid 40514515)
56. Discovery of an Aurora kinase inhibitor through site-specifc dynamic combinatorial chemistry. Cancilla MT, He MM, Viswanathan N, Simmons RL, Taylor M, Fung AD, Cao K, Erlanson DA BIOORG MED CHEM LETT 2008 18 14 3978-3981
57. The synthesis and SAR of 2-amino-pyrrolo[2,3-d] pyrimidines: A new class of Aurora-A kinase inhibitors. Moriarty KJ, Koblish HK, Garrabrant T, Maisuria J, Khalil E, Ali F, Petrounia LP, Crysler CS, Maroney AC, Johnson DL, Galemmo RA BIOORG MED CHEM LETT 2006 16 22 5778-5783 (Pubitemid 44486744)
58. 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identifcation of a potent Aurora kinase inhibitor with a favourable antitumour kinase inhibition profle. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P et al J MED CHEM 2006 49 24 7247-7251
59. Lestaurtinib (CEP701) is a Jak2 inhibitor that suppresses Jak2/Stat5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, Angeles T, Emerson SG, Carroll M, Ruggeri B, Dobrzanski P BLOOD 2008 111 12 5663-5671
60. Jak2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Pardanani A LEUKEMIA 2008 22 1 23-30
61. Aurora kinases as anticancer drug targets. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR CLIN CANCER RES 2008 14 6 1639-1648 (Pubitemid 351471713)
62. Chemical proteomic profles of the Bcr-Abl inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Kocher T et al BLOOD 2007 110 12 4055-4063 (Pubitemid 350248462)